Niagen Bioscience

Niagen Bioscience

Yahoo Finance • last month

Niagen Bioscience to Present at Longevity Investors Conference

LOS ANGELES, September 02, 2026--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management... Full story

Yahoo Finance • 2 months ago

Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit

LOS ANGELES, August 26, 2026--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management wi... Full story

Yahoo Finance • 2 months ago

Does Niagen Bioscience's (NAGE) Walmart NAD+ Push Redefine Its Healthy‑Aging Brand Narrative?

In early August 2026, Niagen Bioscience Inc. reported slightly lower quarterly sales and net income year on year, while also expanding access to its Tru Niagen® healthy‑aging NAD+ supplement via Walmart.com, initially offering 300 mg bottl... Full story

Yahoo Finance • 2 months ago

At a glance: stocks gapping down premarket

[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell on Wednesday. U.S. stock index futures rose on Wednesday as Wall Street looked to continu... Full story

Yahoo Finance • 2 months ago

Niagen Bioscience Inc (NAGE) (Q2 2026) Earnings Call Highlights: E-Commerce Surge and China ...

This article first appeared on GuruFocus. Release Date: August 04, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Niagen Bioscience Inc (NASDAQ:NAGE) reported s... Full story

Yahoo Finance • 2 months ago

Niagen Bioscience outlines 10% to 15% 2026 e-commerce growth while positioning Niagen Plus and NB4168 for 2027 traction

Earnings Call Insights: Niagen Bioscience (NAGE) Q2 2026 MANAGEMENT VIEW * "This quarter marks another important milestone in the evolution of Niagen Bioscience" (CEO & Director Robert Fried) and "today, we are becoming something much... Full story

Yahoo Finance • 7 months ago

U.S. expands Latin America drug fight with joint operation in Ecuador

[Pushpin marking on Ecuador map] Tuangtong Ecuador and the United States have carried out a joint military operation targeting powerful criminal gangs, marking a new phase in Washington’s expanding campaign against drug trafficking groups... Full story

Yahoo Finance • 7 months ago

Niagen Bioscience targets 10–15% revenue growth for 2026 while expanding injectable product line

Earnings Call Insights: Niagen Bioscience, Inc. (NAGE) Q4 2025 MANAGEMENT VIEW * CEO Robert Fried reported, "In the fourth quarter, revenue was $33.8 million, growing 16% year-over-year with net income of $4.1 million. So for the full... Full story

Yahoo Finance • 7 months ago

Niagen Bioscience GAAP EPS of $0.05 beats by $0.03, revenue of $33.84M beats by $2.14M

* Niagen Bioscience press release [https://seekingalpha.com/pr/20424613-niagen-bioscience-reports-30-percent-year-over-year-net-sales-increase-to-129_4-million-103] (NAGE [https://seekingalpha.com/symbol/NAGE]): Q4 GAAP EPS of $0.05 beat... Full story

Yahoo Finance • 8 months ago

Promising Penny Stocks To Consider In February 2026

As February begins, U.S. stock indexes have shown a strong start with the Dow Jones Industrial Average climbing by 515 points and the S&P 500 nearing a record high. While larger market trends capture headlines, investors often overlook sma... Full story

Yahoo Finance • 8 months ago

Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks

As February begins, the U.S. stock market is showing strength, with major indexes like the Dow Jones and S&P 500 posting significant gains. In this context of rising indices, investors often look for opportunities that may offer growth pot... Full story

Yahoo Finance • 11 months ago

Niagen Biosciences Reports Results From First-ever Randomized Trial Of Niagen NR In Long COVID

(RTTNews) - Niagen Biosciences, Inc. (NAGE), a global leader in NAD+ science and healthy ageing, announced results from its first randomised controlled trial evaluating Niagen - a patented nicotinamide riboside (NR) supplementation - in in... Full story

Yahoo Finance • 11 months ago

Niagen Bioscience launches $10M share repurchase program

* Niagen Bioscience (NAGE [https://seekingalpha.com/symbol/NAGE]) has approved a share repurchase program under which the company is authorized to repurchase up to $10M of outstanding common stock over about 24 months. * NAGE +3.05% pr... Full story

Yahoo Finance • 11 months ago

Niagen Bioscience raises revenue growth outlook to 25%-30% for 2025 while expanding clinic and telehealth reach

Earnings Call Insights: Niagen Bioscience, Inc. (NAGE) Q3 2025 MANAGEMENT VIEW * CEO Robert Fried opened by highlighting "another record performance with $34 million in revenue, a 33% increase year-over-year and net income of $4.6 mill... Full story

Yahoo Finance • last year

Discover September 2025's Stocks That May Be Trading Below Estimated Value

As of September 2025, the U.S. stock market is experiencing a mixed performance, with the S&P 500 and Nasdaq reaching new closing highs while the Dow Jones Industrial Average sees a decline ahead of key inflation data releases. In this env... Full story

Yahoo Finance • last year

Byrna Technologies And 2 Other Stocks That May Be Undervalued By The Market

In recent trading, the U.S. stock market has shown mixed performance with the S&P 500 and Nasdaq rising, driven by tech stocks like Alphabet reaching record highs, while the Dow Jones Industrial Average faced slight declines. As Treasury y... Full story

Yahoo Finance • last year

Three Stocks That May Be Undervalued In August 2025

As of late August 2025, the U.S. stock market is experiencing a period of optimism, with major indices like the S&P 500 and Dow Jones Industrial Average reaching record highs. Amid this bullish environment, identifying undervalued stocks c... Full story

Yahoo Finance • last year

3 Undervalued Stocks Estimated To Be 33.1% To 39.9% Below Intrinsic Value

As the U.S. stock market experiences fluctuations with tech stocks sliding and retailers in focus amid a slew of earnings reports, investors are keenly watching for insights from Federal Reserve Chair Jerome Powell's upcoming speech. In su... Full story

Yahoo Finance • last year

3 Stocks Estimated To Be Trading At Discounts Of Up To 46%

As the U.S. stock market experiences a mix of highs and lows, with the Dow Jones Industrial Average touching record levels while the S&P 500 and Nasdaq face declines, investors are keenly observing potential shifts in monetary policy and e... Full story

Yahoo Finance • last year

3 Stocks Estimated To Be Trading Up To 40.8% Below Their Intrinsic Value

As the U.S. stock market navigates a landscape marked by record highs and fluctuating inflation expectations, investors are keenly observing economic indicators that could influence Federal Reserve policy decisions. In this environment, id... Full story